ABOUT US
In over 50 years there was little development in the treatment of chronic kidney disease. At inRegen we are pioneers in the field of diabetic kidney treatment.
We believe there is a better way.
Our passion about curing chronic kidney disease led us to develop a revolutionary cell therapy that harnesses the body’s intrinsic ability to repair and restore damaged kidney tissues to native-like organs and tissues. inRegen's technology has the potential to delay or
eliminate the need for dialysis and organ transplantation.
inRegen’s candidates are designed to become the
standard of care for chronic kidney disease.
HIGHLIGHTS
FDA awarded Fast Track Designation
Presentation at the Alliance for Regenerative Medicine (ARM) Investor Day 2017
ReACT Potential health care cost off-set equals approximately $250K/patient/year
Long-term durability of approximately 4 years
Improves multiple renal endocrine and filtration functions
Partnership with the National Kidney Foundation (NKF) and the American Association of Kidney Patients (AAKP)
